Drugs / Dextran 40
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03070353 | Jul 2015 → Jun 2016 | acute kidney injury, cirrhosis of liver | Ramathibodi Hospital | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06835023 | Jan 2022 → May 2025 overdue | acute pancreatitis | Satu Mare County Emergency Hospital | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| — | NCT07283562 Comparator | Jan 2023 → Oct 2025 | sensorineural hearing loss disorder | The First Hospital of Hebei Medical University | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dextran-40 | “Both groups received a standard regimen (Dextran-40, Ginkgo Biloba Extract, Mecobalamin, and Yufeng Ningxin Dripping Pills).” NCT07283562 ↗2“Dextran 40 in sodium chloride [NaCl] 0.9 grams per liter [g/L] solution” NCT06835023 ↗ |
| Route | Intravenous | “Intravenous Dextran-40 (500 mL, daily for 7 days)” NCT07283562 ↗ |